Research

B12 deficiency research in vegan populations: a 2026 update

Recent literature on serum B12, MMA, holoTC, and the supplementation regimens that work.

The B12 question on plant-based diets is the most-studied of the plant-based nutrient questions. The headline conclusion has been stable for two decades: unsupplemented vegan diets produce B12 deficiency at high frequency, supplementation works reliably, and the clinical assessment battery (serum B12, methylmalonic acid, holotranscobalamin) is well-characterized. The 2024-2026 literature has refined the picture in three ways: better characterization of subclinical deficiency, improved evidence on cyanocobalamin vs methylcobalamin efficacy, and pediatric-and-pregnancy-specific risk quantification.

This update summarizes the recent literature directions and the practical implications for plant-based clinical work.

Subclinical B12 deficiency

The most clinically interesting recent literature concerns subclinical B12 deficiency: the state of elevated methylmalonic acid (MMA) with serum B12 in the apparently-normal range. Subclinical deficiency is associated with measurable but subtle effects (cognitive performance variations, neurological subtleties, cardiovascular risk markers) without the classical clinical presentation of frank deficiency.

Several cross-sectional studies in vegan populations published in 2024-2025 have refined the prevalence estimates:

• Roughly 30-50 percent of unsupplemented vegan adults have elevated MMA, depending on the cohort and the duration of vegan eating.
• Roughly 10-20 percent of vegan adults supplementing with B12 still show elevated MMA, suggesting that supplementation is not always sufficient at all dose levels and that adherence is a meaningful factor.
• Children of vegan mothers who do not supplement during pregnancy or lactation show elevated MMA at higher rates than their mothers in some studies, consistent with the depletion-during-development pattern.

The clinical implication: serum B12 alone is insufficient for clinical assessment in plant-based eaters. Adding MMA (and where available, holoTC) catches subclinical cases that serum B12 misses.

Cyanocobalamin vs methylcobalamin

The 2024-2026 literature includes additional comparative data on cyanocobalamin vs methylcobalamin supplementation. The headline finding has been stable: both forms produce adequate B12 status when used at adequate doses, with cyanocobalamin somewhat more efficient per microgram in some studies and methylcobalamin somewhat more efficient in others. The form choice is not the primary driver of supplementation success; adherence and dose adequacy are.

Two specific findings worth noting:

1. High-dose cyanocobalamin once weekly (1000-2000 mcg) produces equivalent B12 status to daily low-dose supplementation in most adults. This is the simplest adherence regimen for many users.
2. Methylcobalamin sublingual does not produce systematically better B12 status than oral cyanocobalamin tablets. The sublingual route does not provide a meaningful pharmacokinetic advantage at typical supplement doses; the marketing claims to the contrary are not supported by current evidence.

For plant-based clients without specific clinical reasons to prefer one form, cyanocobalamin tablets are the cheapest and most-supported default. For clients who prefer methylcobalamin (some prefer the natural-form framing; some have clinical conditions where it is preferred), the form is acceptable at comparable doses.

Pregnancy and lactation

The 2024-2026 literature has reinforced the case for B12 supplementation during plant-based pregnancy and lactation. Several findings:

1. Maternal B12 status during pregnancy correlates with offspring B12 status at birth and through early infancy. Maternal supplementation is the upstream intervention; failing to supplement during pregnancy can produce infant deficiency that persists into late infancy.
2. Breast milk B12 reflects maternal status, not supplementation alone. A pregnant woman beginning supplementation only in late pregnancy may not have replenished sufficient stores to produce B12-replete breast milk in early lactation. The supplementation should ideally begin pre-conception or in early pregnancy.
3. Pediatric B12 deficiency in infants of unsupplemented vegan mothers has been documented in case series, with severe presentations including failure to thrive, developmental delay, and neurological deficits. The presentations are reversible with prompt supplementation but reversal can be incomplete in delayed-treatment cases.

The clinical guidance is unambiguous: pregnant and lactating plant-based women should supplement B12 reliably, and the supplementation should begin pre-conception or as early in pregnancy as possible. Confirmation of adequate maternal B12 status (serum B12 + MMA) during pregnancy is reasonable and is increasingly part of obstetric protocol for plant-based clients.

Pediatric considerations

For plant-based children, the recent literature reinforces standard pediatric guidance:

• Plant-based infants need either maternal supplementation that maintains adequate breast-milk B12 or direct infant supplementation.
• Plant-based toddlers and children need ongoing supplementation; childhood is not a time when the supplementation case weakens.
• Plant-based adolescents continue to need supplementation, with attention to dose adequacy as body size increases.

The pediatric provider’s protocol controls for specific dosing in children. The general principle is consistent supplementation across the developmental window.

Older adults

Atrophic gastritis reduces intrinsic-factor production with age, which reduces the absorption of food-bound B12 across all populations regardless of diet pattern. Plant-based older adults have a doubled exposure (no animal-product sources plus reduced absorption of fortified-food B12 via the intrinsic-factor pathway). The mitigation is to use higher supplementation doses, which rely on passive (non-intrinsic-factor) absorption that is roughly 1 percent of the dose. A 1000-2000 mcg weekly dose produces 10-20 mcg of absorbed B12 via passive absorption, which is sufficient even with severely reduced intrinsic-factor function.

The 2024-2026 literature has reinforced the case for higher-dose supplementation in plant-based older adults. The recommendation is consistent with non-plant-based older adult guidelines from gastroenterology and geriatrics.

Why supplementation sometimes fails

A small but clinically interesting subset of plant-based eaters supplement reliably and still show elevated MMA. The recent literature has explored several causes:

1. Inadequate dose. A user taking 25 mcg cyanocobalamin daily may be at the edge of adequate; the practical recommendation is 100 mcg daily or 1000-2000 mcg weekly to ensure margin.
2. Adherence less reliable than reported. Self-report of adherence overestimates actual adherence in many studies. Pharmacy-confirmed adherence (refill records) is more reliable.
3. Specific medical conditions affecting B12 absorption: H. pylori infection, gastric surgery, autoimmune pernicious anemia, certain medications (proton pump inhibitors at high doses chronically; metformin in some patients). These conditions warrant clinical evaluation and may require parenteral B12 (injections) rather than oral supplementation.
4. Genetic variants in B12 metabolism. Some individuals have FUT2 secretor variants or other genetic factors affecting B12 metabolism. These cases are unusual and typically managed clinically with higher supplementation doses or alternative forms.

For plant-based clients who supplement reliably but show persistent MMA elevation, evaluation for underlying medical contributors is appropriate.

Practical clinical takeaways

For plant-based clinical work the recent B12 literature reinforces:

1. Supplement reliably: 100 mcg cyanocobalamin daily, or 1000-2000 mcg cyanocobalamin once weekly, or methylcobalamin at comparable doses. Form choice is not the primary driver of success.
2. Test serum B12 + MMA in plant-based clients on the first visit. Repeat every 1-2 years for established supplementing clients; more frequently if clinical concerns arise.
3. Pre-conception and pregnancy supplementation is essential for plant-based women planning pregnancy. Start early and confirm adequate maternal status.
4. Higher-dose supplementation for older plant-based adults due to reduced intrinsic-factor function.
5. Pediatric supplementation across the developmental window.

For more on B12 supplementation practical detail, see our B12 nutrient piece. For the broader clinical context see the AND position paper summary and the EPIC-Oxford findings on stroke risk in vegan populations (which are partially attributed to B12 status).

Citations

Multiple references in the recent B12 literature including American Journal of Clinical Nutrition, British Journal of Nutrition, Public Health Nutrition, European Journal of Clinical Nutrition, and Journal of the Academy of Nutrition and Dietetics. The pediatric case series literature is concentrated in pediatric and developmental journals.

Specific recent reviews on subclinical B12 deficiency in vegan populations have appeared in Advances in Nutrition and in the Journal of the Academy of Nutrition and Dietetics in the 2024-2025 publication window.

Topics: vegan B12 deficiency research · B12 MMA holoTC · cyanocobalamin methylcobalamin · vegan pregnancy B12